Marinus Pharmaceuticals reports Q3 EPS (42c), consensus (41c)

Written by Emily J. Thompson, Senior Investment Analyst

MRNS%

Updated: Nov 12 2024

0mins

Q3 Financial Performance: Sangamo reported Q3 revenue of $8.5 million, falling short of the consensus estimate of $9.4 million, while highlighting significant advancements in their regulatory pathway for ST-920 in Fabry disease.
Pipeline Developments: The company is progressing with its neurology pipeline, having submitted its first IND application for ST-503 aimed at treating intractable pain, and is actively seeking additional funding to enhance its programs and technologies.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Marinus Pharmaceuticals reports Q3 EPS (42c), consensus (41c)

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Pictet North America Advisors Buys 2,703 Shares of MercadoLibre (MELI) for $5.68 Million

Louisbourg Investments Sells 73,600 Shares of OR Royalties for Approximately $2.58 Million

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch